Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Validation of optimized embryo scoring procedures: single-day versus two-day assessment.

Gynecologic and obstetric investigation·2026
Same author

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Cancer research communications·2026
Same author

Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients.

BMJ open·2026
Same author

Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST).

International journal of cancer·2026
Same author

Clinical Outcome Associated With Beta-Lactam Allergy Labels in Hospitalized Patients in Belgium.

Clinical and translational allergy·2026
Same journal

Integrated multi-omics and single-cell analysis of galectins and immune associations in triple-negative breast cancer.

Translational oncology·2026
Same journal

DAZAP2, regulated by miR-125b, contributes to inflammation-related non-small cell lung cancer progression.

Translational oncology·2026
Same journal

Single-cell and machine learning-based neural regulation signature for prognosis prediction and immunotherapy response in lung adenocarcinoma.

Translational oncology·2026
Same journal

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same journal

Fractionated high-dose vitamin c sustains higher plasma trough concentrations in advanced solid tumors: a phase I clinical study.

Translational oncology·2026
Same journal

Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks.

Translational oncology·2026
查看所有相关文章

相关实验视频

Updated: Jun 20, 2025

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

Published on: September 23, 2014

24.0K

在突肉瘤中潜在的可操作目标:组织微阵列研究

Lore De Cock1, Flavia Paternostro2, Ulla Vanleeuw2

  • 1Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.

Translational oncology
|July 19, 2024
PubMed
概括
此摘要是机器生成的。

这项研究发现,像MAGE-A4,NY-ESO-1,YAP1,TAZ,CXCR4和BRD9这样的关键蛋白质在突肉瘤 (SynSa) 组织中表达. 这支持正在进行的研究,研究这种罕见的癌症的新疗法.

关键词:
可操作的目标可操作的目标.免疫组织化学 免疫组织化学突骨肉瘤 (Synovial Sarcoma) 是一个突骨肉瘤.组织微型阵列.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

相关实验视频

Last Updated: Jun 20, 2025

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

Published on: September 23, 2014

24.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 病理学 病理学 病理学

背景情况:

  • 突肉瘤 (SynSa) 是一种常见的软组织肉瘤,对转移性疾病的治疗选择有限.
  • 针对癌症丸抗原 (NY-ESO-1,MAGE-A4),BRD9,YAP1,TAZ和CXCR4的新疗法正在研究中.

研究的目的:

  • 为了研究可操作的治疗标在突肉瘤中的表达.
  • 在大量 SynSa 样本中,将蛋白质表达与临床病理学数据相关联.

主要方法:

  • 来自91个SynSa样本的组织微阵列 (TMA) 的免疫组织化学分析.
  • 蛋白质表达 (MAGE-A4,NY-ESO-1,YAP1,TAZ,CXCR4,BRD9) 与临床病理特征的相关性.

主要成果:

  • 对于MAGE-A4 (69%),NY-ESO-1 (56%),YAP1 (92%),TAZ (51%),CXCR4 (82%) 和BRD9 (100%) 的表达率很高.
  • 与原发性瘤相比,转移性病变中的NY-ESO-1表达更高.
  • 没有发现任何被研究的蛋白质具有显著的预后作用.

结论:

  • 这项研究提供了SynSa.中可操作蛋白质表达的真实数据.
  • 这些标记物的广泛表达支持了正在进行的针对性治疗研究的临床相关性.